D. G. Altman, Systematic reviews in health care: Systematic reviews of evaluations of prognostic variables, BMJ, vol.323, issue.7306, pp.224-228, 2001.
DOI : 10.1136/bmj.323.7306.224

F. Balkwill, C. , and L. M. , Cancer: An inflammatory link, Nature, vol.2, issue.7007, pp.405-406, 2004.
DOI : 10.1016/S1470-2045(03)01196-3

F. Balkwill and A. Mantovani, Inflammation and cancer: back to Virchow? The Lancet 357, pp.539-545, 2001.

F. J. Barrat, T. Meeker, J. Gregorio, J. H. Chan, S. Uematsu et al., Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus, The Journal of Experimental Medicine, vol.32, issue.8, pp.1131-1139, 2005.
DOI : 10.4049/jimmunol.171.6.3296

A. A. Beg, Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses, Trends in Immunology, vol.23, issue.11, pp.509-512, 2002.
DOI : 10.1016/S1471-4906(02)02317-7

M. Buyse, D. J. Sargent, A. Grothey, A. Matheson, A. Gramont et al., Biomarkers and surrogate end points???the challenge of statistical validation, Nature Reviews Clinical Oncology, vol.3, issue.6, pp.309-317, 2010.
DOI : 10.1038/nrclinonc.2010.43

A. Chang, Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC, Lung Cancer, vol.71, issue.1, pp.3-10, 2011.
DOI : 10.1016/j.lungcan.2010.08.022

L. M. Coussens and Z. Werb, Inflammation and cancer, Nature, vol.2, issue.6917, pp.860-867, 2002.
DOI : 10.1006/cyto.1996.0074

M. Dieu-nosjean, M. Antoine, C. Danel, D. Heudes, M. Wislez et al., Long-Term Survival for Patients With Non???Small-Cell Lung Cancer With Intratumoral Lymphoid Structures, Journal of Clinical Oncology, vol.26, issue.27, pp.4410-4417, 2008.
DOI : 10.1200/JCO.2007.15.0284

G. Dranitsaris, N. Beegle, A. Ravelo, T. Kalberer, E. Yu et al., Evaluating the Impact of Bevacizumab Maintenance Therapy on Overall Survival in Advanced Non???Small-Cell Lung Cancer, Clinical Lung Cancer, vol.14, issue.2
DOI : 10.1016/j.cllc.2012.06.002

G. Dranoff, Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol advance online publication, 2011.

B. Drobits, M. Holcmann, N. Amberg, M. Swiecki, R. Grundtner et al., Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells, Journal of Clinical Investigation, vol.122, issue.2, 2012.
DOI : 10.1172/JCI61034DS1

A. Droemann, D. Gerdes, J. Ulmer, A. J. Branscheid, D. Dalhoff et al., Human lung cancer cells express functionally active Toll-like receptor 9, Respiratory Research, vol.60, issue.24
DOI : 10.1016/S1567-5769(00)00050-3

G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, Cancer immunoediting: from immunosurveillance to tumor escape, Nature Immunology, vol.3, issue.11, pp.991-998, 2002.
DOI : 10.1038/ni1102-991

G. P. Dunn, L. J. Old, and R. D. Schreiber, The Three Es of Cancer Immunoediting, Annual Review of Immunology, vol.22, issue.1, 2004.
DOI : 10.1146/annurev.immunol.22.012703.104803

M. Dupage, A. L. Dooley, and T. Jacks, Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase, Nature Protocols, vol.180, issue.8, pp.1064-1072, 2009.
DOI : 10.1038/5007

M. Dupage, C. Mazumdar, L. M. Schmidt, A. F. Cheung, and T. Jacks, Expression of tumour-specific antigens underlies cancer immunoediting, Nature, vol.4, issue.7385, pp.405-409, 2012.
DOI : 10.1038/nature10803

T. M. Earl, I. B. Phd, J. M. Ba, J. P. Wright, N. E. Ba et al., Silencing of TLR4 Decreases Liver Tumor Burden in a Murine Model of Colorectal Metastasis and Hepatic Steatosis, Annals of Surgical Oncology, vol.43, issue.4, pp.1043-1050, 2009.
DOI : 10.1245/s10434-009-0325-8

W. J. Fávaro, O. S. Nunes, F. R. Seiva, I. S. Nunes, L. K. Woolhiser et al., Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer, Infectious Agents and Cancer, vol.7, issue.1, p.14, 2012.
DOI : 10.1186/1750-9378-7-14

Z. Gao, B. Han, J. Shen, A. Gu, D. Qi et al., ERCC1 protein as a guide for individualized therapy of late-stage advanced nonsmall cell lung cancer, Exp Ther Med, vol.2, pp.811-815, 2011.

N. Godin-heymann, I. Bryant, M. N. Rivera, L. Ulkus, D. W. Bell et al., Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation, Cancer Research, vol.67, issue.15, pp.7319-7326, 2007.
DOI : 10.1158/0008-5472.CAN-06-4625

S. González-reyes, L. Marín, L. González, L. O. González, J. M. Del-casar et al., Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis, BMC Cancer, vol.7, issue.Suppl 1, p.665, 2010.
DOI : 10.1517/14712598.7.8.1257

A. D. Gregory and A. M. Houghton, Tumor-Associated Neutrophils: New Targets for Cancer Therapy, Cancer Research, vol.71, issue.7, pp.2411-2416, 2011.
DOI : 10.1158/0008-5472.CAN-10-2583

C. Guiducci, M. Gong, Z. Xu, M. Gill, D. Chaussabel et al., TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus, Nature, vol.203, issue.7300, pp.937-941, 2010.
DOI : 10.1038/nature09102

C. Guiducci, C. Tripodo, M. Gong, S. Sangaletti, M. P. Colombo et al., Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9, The Journal of Experimental Medicine, vol.65, issue.13, pp.2931-2942, 2010.
DOI : 10.1046/j.1523-1747.2002.01869.x

M. Gunzer, H. Riemann, Y. Basoglu, A. Hillmer, C. Weishaupt et al., Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion, Blood, vol.106, issue.7, pp.2424-2432, 2005.
DOI : 10.1182/blood-2005-01-0342

D. Hanahan and R. A. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-674, 2011.
DOI : 10.1016/j.cell.2011.02.013

J. F. Heron, Docétaxel, 2011.

B. Huang, J. Zhao, S. Shen, H. Li, K. He et al., Listeria monocytogenes Promotes Tumor Growth via Tumor Cell Toll-Like Receptor 2 Signaling, Cancer Research, vol.67, issue.9, pp.4346-4352, 2007.
DOI : 10.1158/0008-5472.CAN-06-4067

S. Jiménez-baranda, I. P. Silva, and N. Bhardwaj, Plasmacytoid dendritic cells lead the charge against tumors, Journal of Clinical Investigation, vol.122, issue.2, pp.481-484, 2012.
DOI : 10.1172/JCI61345

M. Karin, T. Lawrence, and V. Nizet, Innate Immunity Gone Awry: Linking Microbial Infections to Chronic Inflammation and Cancer, Cell, vol.124, issue.4, pp.823-835, 2006.
DOI : 10.1016/j.cell.2006.02.016

M. G. Kelly, A. B. Alvero, R. Chen, D. Silasi, V. M. Abrahams et al., TLR-4 Signaling Promotes Tumor Growth and Paclitaxel Chemoresistance in Ovarian Cancer, Cancer Research, vol.66, issue.7, pp.3859-3868, 2006.
DOI : 10.1158/0008-5472.CAN-05-3948

J. Lee, J. Shin, J. Park, S. Song, and G. Choi, Combined treatment with intratumoral injection of dendritic cells and topical application of imiquimod for murine melanoma, Clinical and Experimental Dermatology, vol.171, issue.5, pp.541-549, 2007.
DOI : 10.1046/j.1523-1747.2000.00833.x

F. Ma, J. Zhang, J. Zhang, and C. Zhang, The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice, Cellular and Molecular Immunology, vol.168, issue.5, pp.381-388, 2010.
DOI : 10.1007/s00262-008-0581-7

C. Manegold, D. Gravenor, D. Woytowitz, J. Mezger, V. Hirsh et al., Randomized phase II trial of a tolllike receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer, J, 2008.

A. Mantovani, P. Romero, A. K. Palucka, and F. M. Marincola, Tumour immunity: effector response to tumour and role of the microenvironment, The Lancet, vol.371, issue.9614, pp.771-783, 2008.
DOI : 10.1016/S0140-6736(08)60241-X

A. Maráz, J. Furák, R. Pálföldi, J. Eller, E. Szántó et al., Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation, Anticancer Res, vol.31, pp.1431-1436, 2011.

J. R. Molina, P. Yang, S. D. Cassivi, S. E. Schild, and A. A. Adjei, Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship, Mayo Clinic Proceedings, vol.83, issue.5, p.584, 2008.
DOI : 10.1016/S0025-6196(11)60735-0

A. Ochi, C. S. Graffeo, C. P. Zambirinis, A. Rehman, M. Hackman et al., Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans, Journal of Clinical Investigation, vol.122, issue.11, pp.4118-4129, 2012.
DOI : 10.1172/JCI63606DS1

P. B. Olkhanud, D. Baatar, M. Bodogai, F. Hakim, R. Gress et al., Breast Cancer Lung Metastasis Requires Expression of Chemokine Receptor CCR4 and Regulatory T Cells, Cancer Research, vol.69, issue.14, pp.5996-6004, 2009.
DOI : 10.1158/0008-5472.CAN-08-4619

K. Polyak and R. A. Weinberg, Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits, Nature Reviews Cancer, vol.103, issue.4, pp.265-273, 2009.
DOI : 10.1038/nrc2620

P. Redondo, J. Olmo, . Del, A. L. Cerio, . De et al., Imiquimod Enhances the Systemic Immunity Attained by Local Cryosurgery Destruction of Melanoma Lesions, Journal of Investigative Dermatology, vol.127, issue.7, pp.1673-1680, 2007.
DOI : 10.1038/sj.jid.5700777

S. Rodenhuis, R. J. Slebos, A. J. Boot, S. G. Evers, W. J. Mooi et al., Incidence and Possible Clinical Significance of K-ras Oncogene Activation in Adenocarcinoma of the Human Lung, Cancer Res, vol.48, pp.5738-5741, 1988.

R. Rosell and E. Felip, Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer, Seminars in Oncology, vol.28, pp.37-44, 2001.
DOI : 10.1016/S0093-7754(01)90058-2

R. Rosell, R. V. Lord, M. Taron, R. , and N. , DNA repair and cisplatin resistance in non-small-cell lung cancer, Lung Cancer, vol.38, issue.3, pp.217-227, 2002.
DOI : 10.1016/S0169-5002(02)00224-6

B. Salaun, I. Coste, M. Rissoan, S. J. Lebecque, R. et al., TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells, The Journal of Immunology, vol.176, issue.8, pp.4894-4901, 2006.
DOI : 10.4049/jimmunol.176.8.4894

J. Scoazec and J. Sabourin, 2010??: septi??me ??dition de la classification TNM, Annales de Pathologie, vol.30, issue.1, pp.2-6, 2010.
DOI : 10.1016/j.annpat.2009.12.001

P. Sève and C. Dumontet, Chemoresistance in Non-Small Cell Lung Cancer, Current Medicinal Chemistry-Anti-Cancer Agents, vol.5, issue.1, pp.73-88, 2005.
DOI : 10.2174/1568011053352604

I. Sheyhidin, Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma, World Journal of Gastroenterology, vol.17, issue.32, p.3745, 2011.
DOI : 10.3748/wjg.v17.i32.3745

A. Sica and A. Mantovani, Macrophage plasticity and polarization: in vivo veritas, Journal of Clinical Investigation, vol.122, issue.3, pp.787-795, 2012.
DOI : 10.1172/JCI59643DS1

R. J. Slebos, R. E. Kibbelaar, O. Dalesio, A. Kooistra, J. Stam et al., Oncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung, New England Journal of Medicine, vol.323, issue.9, pp.561-565, 1990.
DOI : 10.1056/NEJM199008303230902

N. C. Stowell, J. Seideman, H. A. Raymond, K. A. Smalley, R. J. Lamb et al., Long-term activation of TLR3 by Poly(I:C) induces inflammation and impairs lung function in mice, Respiratory Research, vol.2, issue.6, p.43, 2009.
DOI : 10.1371/journal.ppat.0020053

URL : https://hal.archives-ouvertes.fr/hal-00432116

J. P. Thiery, H. Acloque, R. Y. Huang, and M. A. Nieto, Epithelial-Mesenchymal Transitions in Development and Disease, Cell, vol.139, issue.5, pp.871-890, 2009.
DOI : 10.1016/j.cell.2009.11.007

A. Thomas and R. Hassan, Immunotherapies for non-small-cell lung cancer and mesothelioma, The Lancet Oncology, vol.13, issue.7, pp.301-310, 2012.
DOI : 10.1016/S1470-2045(12)70126-2

G. Wang, E. Reed, L. , and Q. Q. , Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review), Oncology Reports, vol.12, pp.955-965, 2004.
DOI : 10.3892/or.12.5.955

H. Yang, H. Zhou, P. Feng, X. Zhou, H. Wen et al., Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion, Journal of Experimental & Clinical Cancer Research, vol.29, issue.1, p.92, 2010.
DOI : 10.1093/jnci/dji403

L. Organes-sont-récupérés, dilacérés et placés dans 500?L de PBS 1X avec 16?L soit XXXUI de DNase et 5?L soit XXXUI de libérase